-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TRV-734 in Opium Withdrawal Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TRV-734 in Opium Withdrawal Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TRV-734 in Opium Withdrawal SyndromeDrug Details:TRV-734 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oliceridine in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oliceridine in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Oliceridine in Pain Drug Details:Oliceridine (Olinvyk) is an opioid agonist. It is formulated as...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Osteosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Osteosarcoma Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio) a programmed death-ligand...
-
Company Profile
Trevena Inc – Company Profile
Trevena Inc (Trevena) is a biotechnology company. It discovers and develops G-protein coupled receptor targeted medicines. The company products includes OLINVYK (Oliceridine) injection, TRV045, TRV734 and TRV250. OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain. TRV045 is an oral drug used for the treatment of acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Trevena’s TRV734 is also an oral drug which is used in medication - assisted therapy...
Add to Basket -
Product Insights
Net Present Value Model: Olinvyk
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Olinvyk Drug Details Oliceridine (Olinvyk) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TRV-045
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TRV-045 Drug Details TRV-045 is under development for the treatment of chemotherapy-induced peripheral neuropathy,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TRV-734
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TRV-734 Drug Details TRV-734 is under development for the treatment of opium withdrawal syndrome....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – oliceridine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry oliceridine Drug Details Oliceridine (Olinvyk) is an opioid agonist. It is formulated as solution...
-
Product Insights
Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity. The Migraine pipeline drugs market research report provides comprehensive information on the therapeutics...
-
Product Insights
Chemotherapy Induced Peripheral Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Chemotherapy-induced Peripheral Neuropathy - Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Chemotherapy-induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for...